{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0053317_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"181-926-968-248-343"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11725,"type":"PATENT","title":"University of Milan - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":800,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8377,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* milan
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 292
Search Applicants and Owners separately:Univ* Pavia. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 276
Search Applicants and Owners separately: univ* milan
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 292
Search Applicants and Owners separately:Univ* Pavia. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 276
at least one gastroresistant and enterosoluble polymer selected from: phthalic acid cellulose esters, trimellitic acid cellulose esters, acrylates and polymethacrylates\n
at least one anionic, cationic, amphoteric or non-ionic surfactant;\n
at least one monovalent, divalent or trivalent metal ion salt of a biocompatible and biodegradable polymer having acidic groups, selected from: salts of alginic acid, of hyaluronic acid and of xanthan gum;\n
at least one additional biocompatible and biodegradable polymer selected from: glucans, scleroglucans, mannans, galactomannans, gellans, carrageenans, pectins, polyanhydrides, polyaminoacids, polyamines, xanthans, tragacanth gum, guar gum, xanthan gum, celluloses and derivatives thereof, polyvinylalcohols, polyoxyethylenes, carboxyvinylpolymers, starches, collagens, chitins, chitosans, block copolymers of polyoxyethylene-polyoxypropylene known as poloxamers.\nand wherein said biologically active substances are selected from:\n
flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The microparticulate systems according to claim 1 wherein said at least one gastroresistant and enterosoluble polymer is a polymethacrylate."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The microparticulate systems according to claim 1, wherein said monovalent divalent or trivalent metal ion salt of a biocompatible and biodegradable polymer having acidic groups is a sodium, potassium, lithium, calcium, barium, strontium, zinc, aluminium, iron, or a chromium salt of alginic acid, hyaluronic acid or xanthan gum."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The microparticulate systems according to claim 1, wherein said additional biocompatible and biodegradable polymer is a block copolymer of polyoxyethylene-polyoxypropylene known as poloxamers."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The microparticulate systems according to claim 1, having a diameter of between 1 and 300 microns."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A method for preparation of a gastroresistant pharmaceutical formulation, said formulation for administration of biologically active substances to animals, the method comprising:\n
mixing said biologically active substances with a gastroresistant, biocompatible and biodegradable polymer matrix to obtain the microparticulate systems according to claim 1 in a gastroresistant pharmaceutical formulation."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6, wherein said animals include: porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents and other mammals including humans, fowl and fish."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6, wherein said administration is performed by oral administration."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 8, wherein said microparticulate systems are combined with a liquid or solid diet or used as solid supplements for animal feed."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method for preparation of a medicament for administration to animals according to claim 7, the method comprising:\n
mixing biologically active substances with a gastroresistant, biocompatible and biodegradable polymer matrix to obtain the microparticulate systems according to claim 1 in a medicament,\n
wherein said medicament is for prevention of ulcers; for stimulation of the immune system following increased release of interferons; for slowing gastrointestinal transit and motility with a regulatory effect on electrolyte flux across the intestinal mucosa of the animal and consequent antidiarrhoic activity for the animal; for reduced lipid peroxidation malonaldehyde content; for improved reproductive performance and regularising oestrous cycles; for reduced incidence of placental retention; for reduced incidence of mastitis; and/or for improving respiratory efficiency."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 10, for the preparation of a nutraceutic or a medicament having antibacterial, anti-inflammatory, antioxidant and cell membrane protective action, said nutraceutic or medicament for the treatment of lung disorders characterised by acute or chronic bronchospasm."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 10 wherein the medicament is for improving the quality and organoleptic characteristics of meat, even during storage."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["Animal feeds supplemented with the microparticulate systems according to claim 1."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["Animal feeds supplemented with the microparticulate systems according to claim 1 and non-encapsulated antioxidants."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A production process for providing microparticulate systems, the production process comprising the following steps:\n
a) preparing a solution, suspension or emulsion comprising at least one biocompatible and biodegradable polymer and one anionic, cationic, amphoteric or non-ionic surfactant;\n
b) solubilizing or dispersing at least one biologically active substance in the solution, suspension or emulsion from step a) thus providing a mixture A;\n
c) preparing an aqueous solution of at least one monovalent metal ion salt of a biocompatible and biodegradable polymer thus providing a mixture B;\n
d) adding the mixture B from step c) to the mixture A from step b) thus providing a further mixture;\n
e) preparing a solution or a dispersion of at least one gastroresistant and enterosoluble polymer thus providing a mixture C);\n
f) adding the mixture C from step e) to the further mixture from step d) to provide a solution or suspension; and\n
g) nebulising or extruding the solution or suspension from step f) into an aqueous solution of a soluble divalent or trivalent inorganic ion salt; or\n
h) as an alternative to step g), nebulising and drying the solution or suspension from step f) by means of a spray-dryer."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein said mixture A is a solution, suspension or emulsion comprising at least one biocompatible and biodegradable polymer, one anionic, cationic, amphoteric or non-ionic surfactant and at least one biologically active substance."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 16, wherein the mixture A obtained from step b) is an emulsion or a suspension which is obtained by dissolving an equal amount of a biocompatible and biodegradable polymer and an anionic, cationic, amphoteric or non-ionic surfactant in distilled water, the quantities of the polymer and the surfactant being, respectively, comprised of between: 0.1% and 50% w/v."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein step b) is performed by adding to the solution prepared from step a) the at least one biological active substance with constant stirring until a stable solution, suspension or emulsion is obtained (mixture A), and wherein the quantity of the at least one biologically active substance added being comprised of between 0.1% w/v and 50% w/v."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein said mixture B is an aqueous solution of at least one monovalent metal ion salt of a biocompatible and biodegradable polymer."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein said mixture C is a buffer solution at a pH of between 5 and 9, and comprises a gastroresistant and enterosoluble polymer in a quantity of between 10% and 30% w/v."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15 wherein the mixture B is added to the mixture A in a volumetric ratio of 1:2, and the mixture thus obtained is added to mixture C in a volumetric ratio of 3:1."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein nebulizing the solution or suspension of step f) is performed in step g) through orifices, nozzles, or needles with dimensions between 10 μm and 5000 μm, and extrusion occurs by means of automated, semi-automated microencapsulators, peristaltic, piston or other pumps, or using a manually activated and/or automatic syringe operating at such a speed to produce 10 to 250 drops/minute."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein the aqueous solution of a soluble divalent or trivalent inorganic ion salt of step g) is an aqueous solution of calcium, barium, strontium, zinc, aluminium, iron or chromium chlorides."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein the aqueous solution of a soluble inorganic ion salt of step g) has a concentration of between 0.1 and 2.0 M."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, additionally comprising the step of cross-linking the outer surfaces of the microparticulate systems through the use of cross-linking agents."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 25, wherein said cross-linking agents are in aqueous solutions at concentrations between 0.01 and 5% w/v."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, additionally comprising the step of lyophilizing said microparticulate systems."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein binding agents and other excipients are added to the solution or suspension from step f) to give a wet mass which is extruded by means of a granulator, to give spheroidal granules."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 28, wherein said spheroidal granules have a granulometric distribution comprised of between 50 and 1000 microns."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 28, wherein said spheroidal granules are coated with a gastroresistant and enterosoluble polymer."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The microparticulate systems according to claim 1, having a diameter comprised between 3 and 100 microns."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6, wherein said animals include young of porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents and other mammals including humans, fowl and fish."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The process according to claim 16, wherein step b) is performed by adding to the solution prepared from step a) the at least one biologically active substance with constant stirring until a stable solution, suspension or emulsion is obtained (mixture A), and wherein the quantities of said polymer and said surfactant are comprised of between 0.4% and 30% w/v."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein said mixture C is a buffer solution at a pH of between 7 and 8, and comprises a gastroresistant and enterosoluble polymer in a quantity of between 10% and 30% w/v."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein said mixture C is a buffer solution at a pH of between 5 and 9, and comprises a gastroresistant and enterosoluble polymer in a quantity of between 15% and 25% w/v."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein said mixture C is a buffer solution at a pH of between 7 and 8, and comprises a gastroresistant and enterosoluble polymer in a quantity of between 15% and 25% w/v."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein nebulizing the solution or suspension of step f) is performed in step g) through orifices, nozzles, or needles with dimensions between 300 μm and 2000 μm and extrusion occurs by means of automated, semi-automated microencapsulators, peristaltic, piston or other pumps, or using a manually activated and/or automatic syringe operating at such a speed to produce 10 to 250 drops/minute."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein nebulizing the solution or suspension of step f) is performed in step g) through orifices, nozzles, or needles with dimensions between 10 μm and 5000 μm, and extrusion occurs by means of automated, semi-automated microencapsulators, peristaltic, piston or other pumps, or using a manually activated and/or automatic syringe operating at such a speed to produce 20 to 120 drops/minute."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein nebulizing the solution or suspension of step f) is performed in step g) through orifices, nozzles, or needles with dimensions between 300 μm and 2000 μm, and extrusion occurs by means of automated, semi-automated microencapsulators, peristaltic, piston or other pumps, or using a manually activated and/or automatic syringe operating at such a speed to produce 20 to 120 drops/minute."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 15, wherein the aqueous solution of a soluble inorganic ion salt of step g) has a concentration of between 0.2 and 0.8 M."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 25, wherein said cross-linking agents are protamine sulphate or phosphate, poly-L-lysine hydrobromide, polyvinylamine, or chitosans."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The production process according to claim 28, wherein said spheroidal granules have a granulometric distribution of between 150 and 500 microns."],"number":42,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}